Skip to main content

Advertisement

Table 1 General characteristics of study participants at baseline study

From: The effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease

  Placebo group (n = 30) Probiotic group (n = 30) P 1
Age (year) 61.8 ± 9.8 60.7 ± 9.4 0.64
Familial history (%) 10 (33.7) 11 (36.7) 0.78
Height (cm) 163.2 ± 7.1 162.5 ± 7.2 0.72
Weight at study baseline (kg) 78.2 ± 11.8 80.2 ± 15.3 0.57
Weight at end-of-trial (kg) 78.2 ± 12.0 80.2 ± 15.3 0.56
Weight change (kg) − 0.03 ± 1.1 0.04 ± 1.0 0.78
BMI at study baseline (kg/m2) 29.3 ± 4.1 30.3 ± 5.2 0.42
BMI at end-of-trial (kg/m2) 29.3 ± 4.1 30.3 ± 5.2 0.41
BMI change (kg/m2) − 0.01 ± 0.4 0.06 ± 0.4 0.81
Smoking (%) 3 (10.0) 3 (10.0) 1.00
Aspirin 80 mg (%) 30 (100) 30 (100) 1.00
Statin (%) 30 (100) 30 (100) 1.00
Insulin therapy (%) 8 (26.7) 7 (23.3) 0.76
Antidiabetic drugs (%)
 Monotherpy 16 (72.7) 17 (70.8)  
 Combination therapy 6 (27.3) 7 (29.2) 0.88
Hypertension (%) 22 (73.3) 23 (76.7) 0.76
ACEI/ARB drugs (%) 30 (100) 30 (100) 1.00
Blocker drugs (%)
 β-blocker 28 (93.3) 29 (96.7)  
 Calcium channel blocker 2 (6.7) 1 (3.3) 0.55
Duration of DM (year) 6.8 ± 2.2 6.6 ± 1.9 0.61
Duration of CHD (year) 9.5 ± 2.2 9.3 ± 1.6 0.78
  1. Data are means ± SDs
  2. ACEI Angiontensin converting enzymes inhibitors, ARB Aldosterone receptor blockers, CHD coronary heart disease, DM diabetes mellitus
  3. 1Obtained from independent t-test
  4. Obtained from Pearson Chi square test